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Background. The renin-angiotensin system has been known to
regulate blood pressure and body fluid homeostasis. Several lines
of evidence have shown that renin gene expression and release are
up-regulated by b-adrenergic stimulation, sodium depletion, and
angiotensin converting enzyme inhibition, but down-regulated by
cytokines. To further characterize the human renin gene (hREN)
promoter structure, its regulation, and to identify an appropriate
cell system for study, we examined five cell lines and investigated
drug effects on the hREN promoter expression.
Methods. Using the hREN-luciferase reporter gene constructs
in the DNA transfection assays, approximately 5 kb of the hREN
59 flanking region was assessed for promoter activity in five
different cell lines. Regulation of the hREN promoter activity was
investigated using Y-1 adrenal cells that were transfected with the
hREN-luciferase DNA and were treated with forskolin, calcium
ionophore A23187, phorbol ester, angiotensin II (Ang II), or
cytokines.
Results. Transient transfection analysis showed that the 5 kb
hREN 59 flanking DNA alone was able to confer significant
promoter activity in Y-1 adrenal cells. In transfected Y-1 cells,
luciferase reporter expression was induced by forskolin, sup-
pressed by the calcium ionophore A23187, and phorbol ester in a
dose-dependent manner, but was unaffected by angiotensin II
(Ang II). However, when Y-1 reporter cells were transfected with
human angiotensin II receptor type 1 (AT1) cDNA, hREN
promoter activity was dose-dependently down-regulated by Ang
II, which was blockable by losartan, an AT1-selective antagonist.
Further studies also showed that hREN promoter activity in Y-1
cells was selectively down-regulated by TNFa. Deletion of the
hREN promoter sequences between position 23916 and 22822
not only enhanced hREN promoter activity by approximately
tenfold, but also caused a failure of down-regulation by TNFa. In
contrast, neither interleukin (IL)-1a, IL-1b, IL-2, nor IL-6 exerted
any significant effect.
Conclusions. Together the results suggest that TNFa is a
negative regulator of the hREN expression in the adrenal cells,
and that the TNFa responsiveness may be controlled by elements
located between the positions 23916 and 22822 of the hREN
promoter. Moreover, the Y-1 cell line may provide a valuable
model system for studying renin gene regulation.
The renin-angiotensin system (RAS) plays an important
role in blood pressure and electrolyte regulation in mam-
mals and its activity is thought to be associated with the
pathophysiology of some forms of hypertension [reviewed
in 1, 2]. In addition, the RAS has been implicated in the
control of angiogenesis, growth, and reproduction [3, 4].
Renin, an aspartyl protease, is synthesized primarily within
the juxtaglomerular (JG) cells of the kidney, where it is
stored in granules and released into the circulation by
physiological stimuli. Recently, several lines of evidence
have shown that renin is also produced in a variety of
extrarenal tissues, including adrenal gland, ovary, testis,
brain, heart, submandibular gland (SMG), and macro-
phage/monocyte cells [5–8]. Tissue RAS may regulate the
production of local angiotensin II, a potent vasoactive
peptide, which exerts paracrine or autocrine influences on
local tissue functions.
Renin expression is regulated in a tissue- and cell-specific
manner. Renal and adrenal renin expression and release
are up-regulated by b-adrenergic stimulation [9], sodium
depletion [9–12], and angiotensin converting enzyme inhi-
bition [11, 12]. In contrast, SMG renin expression is
selectively influenced by androgens [13, 14]. Recently,
investigations with hREN transgenic animals showed that,
at most, 3.0 kb of the 59-flanking DNA and 1.2 kb of the
39-flanking DNA of the hREN are sufficient to direct cell-
and tissue-specific expression in vivo [15, 16]. Using re-
porter genes in transient transfection experiments and
DNase I footprinting, several cis-acting regulatory elements
within the 3.0 kb 59-flanking DNA region have also been
demonstrated, which include a pituitary-specific factor
(Pit-1) binding site at 280 to 258 [17], a cAMP-responsive
element between 2148 and 118 [18, 19], an AGE3-like
sequence between 2293 and 2273, an apolipoprotein A1
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regulatory protein-1 (ARP-1)-like sequence at 2259 to
2245 [20], two positive elements at 2892 to 2583, and two
negative elements at 2583 to 2453 and 2149 to 113 [18].
However, little is known regarding the molecular mecha-
nisms by which these regulatory elements control tissue-
and cell-specific renin gene expression. This is due largely
to the lack of appropriate renin-expressing cell lines for
study.
In this study, we extended the hREN 59 flanking se-
quences to approximately 5 kb to further characterize the
hREN promoter and to identify a suitable cell system to
better study renin gene regulation. Here we report that this
DNA region alone was capable of directing luciferase
reporter expression in Y-1 mouse adrenocortical tumor
cells [21]. In stably transfected Y-1 cells, the hREN pro-
moter appears to be regulated in a manner similar to
regulation of the renin gene in kidneys and adrenals in vivo,
suggesting that the Y-1 cell line may serve as a valuable
model system to study renin gene regulation. Furthermore,
we show that hREN promoter is selectively down-regulated
by TNFa in Y-1 cells, and that the newly identified negative
regulatory region (NRR), located at the 59 flanking se-
quences between 23916 and 22822, is responsible for the
TNFa-mediated downregulation of the hREN promoter
activity. These findings provide a molecular basis that link
the inflammatory response, the renin-angiotensin system,
and blood pressure regulation.
METHODS
Cell lines and culture conditions
All five cell lines used in this study were obtained from
the American Type Culture Collections (ATCC). Y-1 cells,
a mouse adrenocortical tumor cell line (CCL 79) [21], were
grown in Hams F-10 medium (Life Technologies, Inc.)
supplemented with 15% horse serum (Hyclone Labs), 2.5%
fetal bovine serum (FBS) (Hyclone Labs), and a standard
mixture of antibiotic and antimycotic agents (Life Technol-
ogies, Inc.). Neuro-2A cells, a mouse neuroblastoma cell
line (CCL 131) [22], JEG-3 cells, a human choriocarcinoma
cell line (HTB-36) [18], and COS-7 cells, a monkey kidney
cell line (CRL 1651), were grown and maintained in
Dulbecco’s modified Eagle’s medium (DMEM; Life Tech-
nologies, Inc.) supplemented with 10% FBS and a mixture
of antibiotic and antimycotic agents. CHO-K1 cells, a
Chinese hamster ovary cell line (CCL 61) were grown in
Ham’s F-12 medium (Life Technologies, Inc.), supple-
mented with 10% FBS and antibiotic-antimycotic agents.
Renin assays
Renin activities in the Y-1 cell lysates and culture media
were determined as previously described [21]. Briefly,
culture media and cell lysates were harvested 24 hours after
culture media was replaced with a serum-free F-10 solu-
tion. The fractions were assayed for renin activity by
quantitating angiotensin I (Ang I) generation with a
GammaCoaty [125I] Plasma Renin Activity Radioimmuno-
assay Kit supplied by INCSTAR Corporation. For total
renin (prorenin and active renin) levels, aliquots of cell
lysates or media were first digested with trypsin (50 mg/ml)
for one hour at 22°C prior to the Ang I generation assays.
Construction of hREN promoter-luciferase reporter
genes
To isolate the genomic DNA fragment containing the
59-flanking sequences of the hREN, a plasmid carrying the
exon I region in an 800 bp XbaI fragment [23] was obtained
from ATCC and used to generate a hybridization probe.
The genomic DNA blot hybridization identified a 10 kb
SacI fragment that contained the sequences immediately
upstream of the 800 bp fragment. The 10 kb SacI fragment
containing the hREN promoter region was cloned by
screening a DNA library of 8 to 12 kb SacI human genomic
fragments. Three shorter overlapping fragments were then
generated by digesting the DNA with the restriction en-
zymes BamHI, NotI, or PstI to yield a 2.7 kb, 4.0 kb, and 5.0
kb 59-flanking DNA fragment, respectively (Fig. 1A). The
proximal ends of the three fragments were trimmed to
delete the coding sequences by exonuclease III treatments
(Erase-A-Base kit; Promega). DNA sequence analysis of
both strands confirmed that the 5.0 kb fragment spans a
region of 24929 to 140, relative to the transcription
initiation site. The nucleotide sequence data has been
reported and appears in the GenBank, EMBL, and
DDBJ Nucleotide Sequence Databases under the accession
number U12821.
The promoterless plasmid vector containing the lucif-
erase reporter gene, pSVOAL [24], which was used to
construct fusion genes, was a generous gift of Dr. Suresh
Subramani, University of California at San Diego. The four
DNA constructs studied and reported here are: 25.0 kb
hREN/pSVOAL (that is, 5.0Luci), 24.0 kb hREN/
pSVOAL (4.0Luci), 22.7 kb hREN/pSVOAL (2.7Luci),
and a deletion mutant of 5.0Luci in which the sequences
between 23916 and 22822 were removed (that is, 3.5Del).
The fusion gene constructs were confirmed by nucleotide
sequencing on both strands.
DNA transfection and luciferase assays
Transient DNA transfections into the five different cell
lines were performed using Lipofectin reagents (1 mg/ml;
Life Technologies, Inc.) and a pSV-b-galactosidase (pSV-
bgal) plasmid (Promega) as an internal control for normal-
izing the plate-to-plate transfection efficiency. Cells were
plated in six-well plates (25,000 cells per well) and trans-
fected using 30 ml of Lipofectin reagents plus 5 mg of
pSV-bgal DNA and an equal molar ratio of the target DNA
per well. Cells were placed into complete culture media six
hours (for CHO-K1 and COS-7 cells) or 18 hours (for
JEG-3, Y-1, and Neuro-2A cells) after the transfection. For
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drug effect studies, cells were allowed to recover for 24 to
36 hours before treatment with drug or vehicle (0.1%
DMSO) alone. For luciferase activity determinations, cells
were washed with 3 ml of phosphate buffered saline (PBS)
without Ca21 or Mg21 and were then lysed with 100 ml of
a cell lysis buffer containing 25 mM Tris-phosphate, pH 7.8,
2 mM DTT, 2 mM 1,2-diaminocyclohexane-N,N,N0,N9-tet-
raacetic acid, 10% glycerol, and 1% Triton X-100 (Pro-
mega). Cell lysates were incubated for 30 minutes at room
temperature. A 20 ml aliquot was assayed for luciferase
activity using 100 ml of the luciferase assay reagent [20 mM
Tricine, 1.07 mM (MgCO3)4Mg(OH)2
.5H2O, 2.67 mM
MgSO4, 0.1 mM EDTA, 33.3 mM DTT, 270 mM coenzyme
A, 470 mM luciferin, 530 mM adenosine 59-triphosphate
(ATP), final pH 7.8]. Light production was immediately
measured with a luminometer (Model ML1000; Dynatech
Laboratories) following automatic dispensing of the sub-
strate D-luciferin. To normalize for plate-to-plate transfec-
tion efficiency, the same cell lysate was also assayed for
b-galactosidase activity.
Stable transfectants of Y-1 cells
To generate stable transfectants, the hREN reporter
construct was cotransfected into Y-1 cells with a pWLneo
plasmid (Stratagene) containing a neomycin-resistant gene
using the protocol described above. The neomycin-resistant
stable transfectants were selected using 400 mg/ml of the
neomycin analog G418 (Sigma) in complete media. Sub-
clones were then grown up in 24-well plates and tested for
luciferase activity. Clones that were tested positive for both
G418-resistance and luciferase activity were expanded. A
genomic DNA blot hybridization technique was used to
quantitate the number of copies transfected into each
clone. Briefly, genomic DNA isolated from each cell line
Fig. 1. Plasmid construction and expression of
the hREN-luciferase reporter genes in
transiently transfected cells. (A) The
construction strategy and the maps of the
hREN promoter-luciferase fusion genes.
Restriction sites are shown as: S, SacI; P, PstI;
N, NcoI; B, BamHI. AUG represents the
translation initiation codon of the reporter
luciferase gene. (B) Relative luciferase activities
expressed in the cell lines transiently
transfected with pSVOAL, 2.7Luci, 4.0Luci, and
5.0Luci, respectively. In these transient
transfection experiments, cells (25,000 cells per
well) were cotransfected with a pSV-bgal
plasmid and luciferase activities were
normalized to b-galactosidase activities to
adjust for differences in transfection efficiency.
Symbols are: ( ) Y-1; (  ) Neuro-2A; (f) JEG-3; (
  
  
  ) CHO-K1; (‘) COS7. Luciferase
activities in the transected CHO-K1 and COS
cells were negligible (close to the baseline).
Results are given as mean 6 SEM of the
percentage of luciferase activity detected in the
2.7Luci-transfected Y-1 cell lysate. Each bar
represents three to five independent
transfections in triplicate wells.
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was digested with SacI enzyme, run out on an agarose gel,
transferred to a HyBond N1 (Amersham) membrane, and
probed with a 918 bp hREN/Luci fusion DNA fragment
generated by a PCR reaction with an upstream primer:
59-ATGCCTGGCCCCTCTACTCTTATA (bases 2535 to
2512 of hREN) and a downstream primer: 59-GCG-
CAACTGCAACTCCGATAAAT (bases 362 to 339 of
luciferase coding region). The number and intensity of the
hybridizable fragments in the genome determined the copy
number. Additionally, a PCR analysis was performed to
confirm that the clones did not contain chromosomal DNA
rearrangement. The 5.0S61 clonal cell line described in this
study contained two to three copies of the 5.0Luci fusion
plasmid.
Semiquantitative reverse transcription-polymerase chain
reaction
Total RNA (250 to 500 nanograms each) prepared from
Y-1 or reporter cells was used for first strand cDNA
synthesis, according to the protocols provided with the
Perkin Elmer’s reverse transcription-polymerase chain re-
action (RT-PCR) kit. The amplification reactions were
then performed, which involved denaturation at 96°C for
two minutes, followed by 35 cycles of 96°C, two minutes,
57°C, 45 seconds, 72°C, 60 seconds, and a final extension at
72°C for seven minutes. The primers used for mouse renin
mRNA detection were: upstream primer 59-CCCTGTCTT-
TGACCACATTCTCTC-39, downstream primer 59-TTG-
GCTTGGCCTAGGGTTACT-39. Primers for the detec-
tion of IL-1b, IL-1R, TNFa, TNFR I, TNFR II, and
GAPDH mRNA were purchased from Clontech Laborato-
ries, Inc.
Drugs
The drugs used in this study were obtained from the
following vendors: forskolin, Ca21 ionophore A23187,
phorbol myristate acetate (PMA), and angiotensin II from
Sigma; TNFa, IL-1a, IL-1b, and IL-2 from Boehringer
Mannheim; and IL-6 from Life Technologies, Inc.
RESULTS
Human renin gene promoter activity in the transfected
cells
To further characterize the hREN promoter and to
identify a suitable cell system to better study renin gene
regulation, three overlapping hREN-luciferase reporter
genes were constructed, as shown in Figure 1A, and their
promoter activities were assessed in five established cell
lines by transient transfection assays. The three hREN-
luciferase fusion constructs tested were 2.7Luci, 4.0Luci,
and 5.0Luci, each containing the hREN 59-flanking se-
quences of 22822 to 140, 23916 to 140, and 24929 to
140, respectively. The five cell lines used in these experi-
ments included two renin expressing cell lines (Y-1 and
Neuro-2A) and three non-renin expressing cell lines
(JEG-3, CHO-K1 and COS-7). To normalize for plate-to-
plate transfection efficiency, cells were cotransfected with
the pSV-bgal plasmid, in which the b-galactosidase gene is
driven by a strong and non-selective SV40 early promoter
and enhancer. In this study, we routinely obtained a
luciferase value of 2,500 to 3,000 light units from 20 ml
lysates of Y-1 cells transfected with the 2.7Luci plasmid,
whereas a cell-free empty well yielded a background value
of 2 to 3 light units.
Results summarized in Figure 1B demonstrate that all
three reporter constructs exhibited more than a sevenfold
greater luciferase activity in Y-1 cells than in Neuro-2A
cells, a very low activity in JEG-3 cells, and were inactive in
COS-7 or CHO-K1 cells. Transfection with the promoter-
less vector pSVOAL plasmid yielded a negligible (,30 light
units) luciferase activity. It was also noted that transfections
with the 4.0Luci and 5.0Luci plasmids resulted in a consis-
tent and significantly lower luciferase activity in both Y-1
and Neuro-2A cells than those detected in the 2.7Luci-
transfected cells. The luciferase activities in the 4.0Luci
transfected Y-1 and Neuro-2A cells were reduced by 52%
and 45%, respectively. Transfections with the 5.0Luci con-
struct caused a further reduction in the luciferase expres-
sion with only 18% and 15%, respectively, of the activities
detected in the 2.7Luci-transfected Y-1 and Neuro-2A
cells. In contrast, a high level (30,000 to 40,000 light units)
of b-galactosidase gene expression was consistently de-
tected in all five transfected cell lines, regardless of the cell
type or reporter gene construct used. Together these results
suggest that the sequence information carried in the hREN
59-flanking region of 22822 to 140 alone is sufficient to
direct a cell-type specific expression. However, additional
negative regulatory sequences may reside within the re-
gions between 24929 and 22822, with the region between
23916 and 22822 having a more pronounced effect.
Characterization of the Y-1 cell line
To ascertain the utility of the Y-1 cell line for studying
renin gene regulation, the renin gene and renin production
in the Y-1 cells were further characterized. First, cell lysates
and culture media harvested from the Y-1 cultures were
analyzed for renin activity by measuring Ang I generation
with an INCSTAR renin activity assay kit. As a result, total
renin activity in the cell lysate was found to be 1.42 6 0.5 ng
Ang I/25,000 cells/hr (mean 6 SEM, N 5 3) with 87% of the
activity derived from active renin, while the culture media
contained renin activity of 0.785 6 0.094 ng Ang I/ml/hr
(mean 6 SEM, N 5 3). In contrast, the culture media
without incubation for Ang I generation gave a much lower
value of 0.157 6 0.025 ng Ang I/ml/hr (mean 6 SEM, N 5 3),
presumably derived from the endogenously secreted Ang I.
Subsequently, a PCR analysis was performed to deter-
mine whether the Y-1 genome carries one or two renin
genes. Based on the previous finding that the mouse Ren-2
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gene has two additional insertions not found in the 59-
flanking region of the Ren-1 gene [25], a primer set was thus
designed to differentiate the Ren-1 from the Ren-2 gene.
Our data showed that only the 748 bp product (correspond-
ing to 2 669 to 1 79 of the Ren-1 gene) was obtained from
the Y-1 and the one-renin gene strain C57BL/10 mouse
genomic DNA template (data not shown). By contrast,
both the 1100 bp (corresponding to 21021 to 179 of the
Ren-2 gene) and 748 bp fragments were generated with the
two renin-gene strain DBA/2J genomic DNA (data not
shown). These results confirmed that similar to the human
and rat, the Y-1 cell line contains only the Ren-1 gene in the
genome.
Effects of forskolin, calcium ionophore, phorbol ester,
and angiotensin II on hREN promoter activity
Regulation of the hREN promoter activity was investi-
gated with the 5.0S61 Y-1 cells stably transfected with the
5.0Luci plasmids. First, cells were treated for six hours with
agents known to regulate renin gene expression, including
forskolin [9], phorbol ester PMA [26, 27], the calcium
ionophore A23187 [26, 27], and angiotensin II (Ang II) [11,
12, 28]. All these drugs were tested at four concentrations:
0.01 mM, 0.1 mM, 1.0 mM, and 10 mM. The results summa-
rized in Figure 2 demonstrate that the basal luciferase
activity expressed in the 5.0S61 cells was dose-dependently
stimulated by forskolin, suppressed by the calcium iono-
phore A23187, and by PMA, but was unaffected by Ang II.
Similar patterns were obtained in parallel studies with the
2.7S52, and 4.0S12 cell lines, in which Y-1 cells were stably
transfected with the 2.7Luci, and 4.0Luci plasmids, respec-
tively.
To address whether the failure of hREN promoter to
respond to Ang II is due to the lack of Ang II receptors in
Y-1 cells, as previously reported [29], the 5.0S61 cells were
transfected with human Ang II receptor (AT1 subtype)
cDNA as well as the pSVbgal plasmid, and effects of Ang
II on luciferase expression were assessed. Results shown in
Figure 3 demonstrate that the relative luciferase activity in
the AT1-transfected cells were dose-dependently inhibited
by Ang II, and the Ang II-mediated inhibition was blocked
by a treatment with losartan, an AT1-selective antagonist,
at 1 mM concentrations. These results suggest that the
signaling system coupled to Ang II receptor activation and
downstream renin gene suppression may exist in Y-1 cells,
and the failure of Y-1 cells to respond to Ang II is resulted
from a lack of Ang II receptor expression in this cell line.
Regulation of the hREN promoter activity by cytokines
To investigate the effects of cytokines on hREN tran-
scription in adrenal cells, stably transfected 5.0S61 cells
were treated for 24 hours with either TNFa, IL-1a, IL-1b,
IL-2, or IL-6 at a concentration of 0, 2, 10, 20, and 100
ng/ml, respectively. The results shown in Figure 4 reveal
that the reporter luciferase expression was selectively and
dose-dependently inhibited by the treatment with TNFa. In
contrast, treatment with IL-1a, IL-1b, IL-2, or IL-6 did not
exert any significant effect. To rule out the possibility that
the reduced luciferase expression caused by TNFa may be
a result of cytotoxicity, a parallel cytotoxicity assay (MTT
assay, Promega) was performed. It was found that, under
the experimental conditions, TNFa was not cytotoxic to the
5.0S61 cells. Furthermore, to exclude the possibility that
the inhibitory effect observed in our study may be due to a
tonic suppression via TNFa, mouse renin activities in the
5.0S61 cell lysates were measured. It was found that renin
activities (ng Ang I/25,000 cells/hr) were reduced by 32%
(0.92 6 0.10 vs. 1.38 6 0.17 in the untreated controls) and
43% (0.78 6 0.09 vs. 1.38 6 0.17 in the controls), after
Fig. 2. Effects of forskolin, calcium ionophore,
phorbol ester, and angiotensin II on luciferase
expression in stably-transfected 5.0S61 cells.
The 5.0S61 cells were plated at 50,000 cells per
well, then incubated for six hours with the
following compounds at concentrations
indicated, and cell lysates were prepared for
luciferase assays. Compounds used were
forskolin (FK), calcium ionophore (A23187),
phorbol myristate acetate (PMA), and
angiotensin II (Ang II), respectively. Results
are given as mean 6 SEM of the percentage of
luciferase activity in the untreated 5.0S61 cell
lysates. Each bar represents three independent
transfections in triplicate wells. Symbols are:
(f) untreated; (p) 0.1 mM; ( ) 0.10 mM; (;)
1.00 mM; (M) 10.0 mM.
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exposure of 5.0S61 cells for 24 hours with TNFa at 20 and
100 ng/ml, respectively.
The TNFa-induced down-regulation was further verified
by assessing the effect of TNFa on endogenous renin
mRNA expression in Y-1 cells. Two hundred and fifty
nanograms of total RNA isolated from Y-1 cells, with or
without TNFa treatment, were analyzed by a semiquanti-
tative RT-PCT method, in which mRNAs for both mouse
renin and GAPDH genes were amplified simultaneously.
Results shown in Figure 5 confirm that TNFa dose-
dependently down-regulated the endogenous renin mRNA
expression in Y-1 cells without affecting the GAPDH
expression. The level of inhibition appeared to be consis-
tent with the reporter luciferase data. Together these data
suggest that the TNFa effect is renin promoter-specific,
because both transfected hREN promoter and the endog-
enous mouse renin promoter in Y-1 cells were down-
regulated by TNFa.
Previously it was demonstrated that IL-1b and TNFa
inhibited the synthesis and release of renin from human
decidual cells [30]. Independently, Petrovic et al reported
that IL-1b down-regulated renin gene transcription in
mouse kidney As4.1 cells and that DNA sequence(s)
mediating that effect may reside within the 4.1 kb upstream
of the mouse Ren1c gene [31]. To address the discrepancies
between our finding in Y-1 cells and their observations, five
hundred nanograms of total RNA isolated from cultured
Y-1 cells were examined by the RT-PCR analysis (Methods
section) to determine the mRNA expression of IL-1b (that
is, 563 bp), TNFa (354 bp), and their respective receptors
IL-1R (710 bp), TNFR I (371 bp), and TNFR II (636 bp).
Results shown in Figure 6 demonstrate that neither IL-1b
nor TNFa mRNA was expressed in the Y-1 cells. Further-
more, no detectable RT-PCR product representing the
IL-1 receptor mRNA was observed, whereas both TNFR I
and TNFR II products were obtained. As seen in Figure 6,
both the positive controls (respective cloned cDNA tem-
plates) and negative controls (RNA without reverse tran-
scription) behaved well in the RT-PCR experiments, as
predicted. These findings support the notion that the
failure of Y-1 cells to respond to IL-b may result from the
Fig. 3. Effect of Ang II treatment on luciferase
expression in 5.0S61 cells transiently
transfected with human AT1 receptor cDNA.
The 5.0S61 cells were plated at 25,000 cells per
well, then transfected with either pSVL vector
plasmid (Pharmacia) or pSVL containing
human AT1 receptor cDNA, using the
lipofectin reagent for six hours. After
incubation in the complete media for two days,
cells were treated for 14-hours without Ang II
(0.1% DMSO instead), with Ang II alone, or
with Ang II and losartan, at concentrations
indicated. Subsequently, cell lysates were
analyzed in the luciferase assays. Results are
given as mean 6 SEM of the percentage of
luciferase activity in the untreated 5.0S61 cell
lysates. Each bar represents two independent
experiments in triplicate wells.
Fig. 4. Effects of cytokines on luciferase expression in 5.0S61 cells. The
5.0S61 cells were plated at 50,000 cells per well and incubated for 24 hours
with the cytokine, as shown, at the concentrations of 0, 2, 10, 20, and 100
ng/ml, respectively, and cell lysates were analyzed in the luciferase assays.
Results are given as mean values of the percentage of luciferase activity in
the untreated 5.0S61 cell lysates. Each line represents three independent
experiments in triplicate wells. Symbols are: (M) TNFa; (L) IL-1a; (E)
IL-1b; () IL-2; (µ) IL-6.
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lack of IL-1 receptor expression in this cell line. Further-
more, the TNFa-mediated down-regulation of renin gene
expression is not modulated by an autocrine or paracrine
mechanism.
Negative regulatory region and TNFa responsiveness
To determine the regulatory region of the hREN pro-
moter involved in the TNFa-mediated down-regulation, a
deletion mutant, 3.5Del, was generated in which the NcoI-
BamHI fragment containing the sequences between 23916
and 22822 was removed from the 5.0Luci plasmid. The
luciferase expression in Y-1 cells transiently transfected
with the 5.0Luci or the 3.5Del plasmids was then assessed.
Data shown in Figure 7 demonstrate that Y-1 cells tran-
siently transfected with the 3.5Del mutant elicited approx-
imately a tenfold increase in luciferase activity than those
transfected with the 5.0Luci plasmid. Nevertheless, the
deletion did not affect the inducibility by forskolin, an
adenylate cyclase activator known to up-regulate renin
expression. These results provide strong evidence that the
DNA region between 23916 and 22822 hREN, termed the
new negative regulatory region (NRR), may contain addi-
tional regulatory signals to down-regulate hREN transcrip-
tion.
To determine whether the NRR is involved in TNFa-
mediated down-regulation, the effect of NRR deletion on
TNFa responsiveness was assessed. As shown in Figure 7,
the luciferase activity in the Y-1 cells transiently transfected
with 5.0Luci plasmid DNA was dose-dependently inhibited
by treatments with TNFa, similar to what was observed in
the 5.0S61 stably transfected cells. Surprisingly, in a sharp
contrast, the luciferase expression in the 3.5Del-transfected
cells was not affected by TNFa, regardless the concentra-
tion used. To ascertain that the effect observed was not an
experimental artifact, renin production in the same trans-
fected cells was examined. We found that despite the lack
of effect of TNFa on reporter gene expression in 3.5Del-
transfected cells, endogenous mouse renin production was
reduced by 30%, and 45% (vs. untreated controls) after
exposure to TNFa for 24 hours, at 20 ng/ml and 100 ng/ml,
respectively. Taken together, these results suggest that the
TNFa-mediated down-regulation of hREN expression in
Y-1 adrenal cells is determined by the NRR, and deletion
of the NRR caused a failure to respond to TNFa.
Fig. 5. Effect of TNFa treatment on renin mRNA expression in Y-1 cells. Two hundred and fifty nanograms of total RNA isolated from Y-1 cells treated
with 0, 10, 20, or 100 ng/ml TNFa, respectively, for 24 hours, were reverse transcribed and amplified for 35 cycles for analysis of renin mRNA expression.
Primers for GAPDH were added in the same RT-PCR tube as an internal control. The TNFa-induced reduction in renin mRNA levels were normalized
with the GAPDH mRNA levels. Results are given as the percentage of renin mRNA levels detected in the untreated Y-1 cells. Each point represents
mean 6 SEM obtained from two independent RT-PCR experiments.
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DISCUSSION
Numerous studies using a variety of reporter cell systems
have attempted to identify the cis-acting regulatory ele-
ments involved in transcriptional control of the hREN
expression. The major limitation of much of this work is
that the studies were not performed in cells that express
renin, such as the use of JEG-3 [18]. Consequently, the
physiologically relevant transcription factors that signal
proper regulation of the renin gene were absent. Recently,
a mouse kidney cell line, As4.1, established from a mouse
kidney tumor by transgene-targeted tumorogenesis [32],
several primary chorionic cells [26] and a pulmonary carci-
noma cell line CALU-6 [33] were reported to endogenously
express renin, thus providing useful systems for studying
hREN gene regulation. Among them, since the pulmonary
renin and chorionic renin have not been demonstrated to
play physiological roles in blood pressure homeostasis,
CALU-6 and chorionic cells may not be suitable for use
when addressing renin gene expression in blood pressure
regulation. In the present study, we show that Y-1 cells
express and secrete active renin. We also show that the
hREN promoter alone, without additional heterologous
regulatory sequences, is capable of directing a high level of
reporter luciferase expression in the Y-1 cells. Although
previous reports have indicated that approximately equal
amounts of the active renin are produced in both Y-1
adrenal tumor [21] and Neuro-2A neuroblastoma cells [22],
the hREN promoter activity is approximately seven times
higher in the Y-1 cells than in the Neuro-2A cells. It is
unclear whether the differences we observed resulted from
the differences between human and mouse renin promot-
ers, or were a consequence of differences in the post-
transcriptional regulation of the luciferase expression in the
two cell systems.
Consistent with previous reports for renal [9], adrenal [9]
and chorionic renin [26], hREN promoter activity in Y-1
cells can be readily induced by treatment with forskolin in
a time-dependent (data not shown) and dose-dependent
manner. This induction is presumably mediated through an
elevation of intracellular cAMP levels. Conversely, the
hREN promoter activity in Y-1 cells is down-regulated by
calcium ionophore A23187 and by phorbol ester. Although
this is opposite from the results seen in the primary
chorionic cells [26], it is in good agreement with the results
observed in primary JG cells [27], suggesting that the
hREN gene transcription may be regulated by protein
kinase C (PKC) activation or elevation of intracellular
calcium concentration in a cell-type specific manner. In
contrast to the chorionic cells, renin expression in the
kidneys and adrenals may be coordinately regulated. Our
data are also consistent with the notion that angiotensin II
(Ang II) serves as a negative feedback regulator in vivo to
suppress renal and adrenal renin expression [11, 12, 28],
because activation of type I Ang II receptor (AT1) was
previously shown to increase calcium concentration in
target cells [34]. Our studies indicated that hREN promoter
in the 5.0S61 reporter cells did not respond to Ang II,
which is also consistent with the previous report showing
that no detectable 125I-[Sar1,Ile8]Ang II binding was ob-
served in Y-1 cells [29]. Nevertheless, when 5.0S61 cells
were transfected with a recombinant human Ang II recep-
tor (AT1) plasmid, the luciferase reporter expression was
down-regulated, in a dose-dependent manner, by Ang II,
and the Ang II-induced down-regulation was blocked by
Fig. 6. mRNA expression of cytokines and
cytokine receptors in Y-1 cells. Five hundred
nanograms of total RNA isolated from cultured
Y-1 cells were reverse transcribed and
amplified, using target specific primers, for 35
cycles for analyzing mRNA expression of
cytokines (IL-1b, and TNFa), and cytokine
receptors (IL-1 receptor, TNF receptor I, and
TNF receptor II). Lanes shown are: (1) positive
control templates for each respective gene
(provided by Clontech Laboratories); (2) Y-1
total RNA; (3) Y-1 total RNA without reverse
transcription. Size marker (M) contains
fragments of (from top to bottom) 1000, 700,
525, 500, 400, 300, 200, 100, and 50 bp. The
RT-PCR products representing the respective
mRNA are marked with asterisks (*).
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the AT1 receptor antagonist, losartan. These results sug-
gest that the signaling effector system linking the Ang II
receptor activation and the downstream renin gene sup-
pression is intact in Y-1 cells, as are those seen in the renal
and adrenal tissues. Thus, Y-1 cell line may provide a
valuable model system for studying regulation of adrenal
renin gene expression and its involvement in blood pressure
control. This view was exemplified by the findings that an
elevated adrenal renin-angiotensin system in the hyperten-
sive TGR(mREN2)27 transgenic rats might be responsible
for the fulminate hypertension [35].
In contrast to the previous report demonstrating that
TNFa and IL-1 can stimulate renin secretion by rat renal
cortex [36], recently two lines of evidence have shown that
cytokines can modulate renin gene expression and release.
Jikihara, Poisner and Handwerger demonstrated that
TNFa and IL-1b inhibited the synthesis and release of
renin from cultured human decidual cells [30]. Indepen-
dently, Petrovic et al reported that IL-1b can down-
regulate renin gene expression in As4.1 mouse renal cell
line [31]. Our finding of renin gene down-regulation in
adrenal cells by TNFa at the physiological concentrations
[37] supports the notion that modulation of hREN expres-
sion by TNFa may contribute, in part, to the pathogenesis
of sepsis-associated hypotension during acute inflamma-
tion.
Deletion and functional mapping analyses have previ-
ously identified several functional cis-acting regulatory el-
ements in the hREN 59-flanking sequences. These include
a Pit-1 binding site between 280 and 258 [17], a cAMP-
responsive element (CRE) between 2148 and 118 [18, 19],
a negative control element between 2583 and 2453, a
positive element between 2892 and 2583, and a renin gene
enhancer between 2453 and 2149 [18]. In addition, motif
searches have uncovered other potential regulatory se-
quences, including a zinc finger protein binding site be-
tween 2167 and 2157, an AP4/GT-2A binding site be-
tween 2199 and 219 [18], an ARP-1 like sequence
between 2259 and 2245 [20], an AGE-3 like sequence
between 2293 and 2273 [20], an HNF-1 binding site
between 2395 and 2389, and an estrogen responsive
element between 2622 and 2595 [20]. However, these
sequence motifs, with the exceptions of the Pit-1 and the
CRE sites, have not been shown to have in vivo functional
activity. In the present study, we extended the hREN
promoter sequence to 24929 and showed that the NRR
region between 23916 and 22822 functions as a negative
regulator for hREN transcription in Y-1 adrenal cells, and
Fig. 7. Effects of forskolin and TNFa on luciferase expression in Y-1 cells transiently-transfected with the 5.0Luci or 3.5Del plasmid. Y-1 cells (25,000
cells per well) were transiently transfected with pSVOAL (promoterless plasmid), 5.0Luci, or 3.5Del plasmid (A), as well as the pSV-bgal plasmid for
normalizing differences in transfection efficiency (Methods section). At 36 hours after transfection, cells were treated for 24 hours with vehicle 0.1%
DMSO, 5 mM forskolin, or TNFa at concentrations indicated, and luciferase activities in the cell lysates were assayed. Results (B) are given as mean 6
SEM of the percentage of luciferase activity detected in the 5.0Luci-transfected cells from two independent transfections in triplicate wells.
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this region may determine the responsiveness of hREN
promoter to TNFa. Our observation is consistent with the
recent report presented by Petrovic et al in which they
demonstrated that DNA sequence(s) involved in IL-1b-
mediated down-regulation of renin gene transcription in
mouse kidney As4.1 cells are positioned within the 4.1 kb
upstream of the mouse Ren1c gene [31]. In fact, motif
searches for the NRR region have identified three putative
cytokine responsive elements [38] positioned between
23373 and 23367 (GAACTGGGGTTCAGTTAGTCAG-
CATCT), 23160 and 23154 (CCACAAAATTTCAGT-
TATGTCAGTCTT), and 23046 and 23040 (CATCA-
CATTATACCTGAAGACTAAGTT), respectively. It
remains to be investigated whether any of these potential
cytokine responsive elements is involved in the TNFa-
mediated hREN downregulation in vivo.
In summary, we have demonstrated that Y-1 cell line
provides a valuable model system to study hREN gene
regulation. Further studies will be required to determine
whether hREN is modulated by TNFa in adrenal glands in
vivo. In addition, a detailed structural dissection and func-
tional analysis of the NRR, including identification of
specific cis-acting TNFa-responsive element(s) within the
NRR and transcription factors that bind to the TNFa-
responsive elements in the target cells, will be needed to
unravel the mechanisms by which the NRR controls the
responsiveness to TNFa.
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APPENDIX
The abbreviations used in this paper are: Ang, angiotensin; ARP-1,
apolipoprotein A1 regulatory protein-1; AT1, angiotensin II receptor type
1; bp, base pair; CRE, cAMP responsive element; DMEM, Dulbecco’s
modified Eagle’s medium; hREN, human renin gene; kb, kilobase pairs;
IL, interleukin; NRR, negative regulatory region between 23916 and
22822 of hREN promoter; PCR, polymerase chain reaction; Pit-1,
pituitary-specific factor; PMA, tetradecanoyl-12-O-phorbol myristate-13-
acetate; RAS, renin-angiotensin system; RT-PCR, reverse transcription-
polymerase chain reaction; SMG, submandibular gland; TNF, tumor
necrosis factor; Y-1 cells, mouse adrenocortical tumor cell line.
Reprint requests to Ling-Sing K. Chen, Ph.D., Department of Molecular
Biology and Medical Technology, Union Chemical Laboratories, Industrial




1. SEALEY JE, LARAGH JH: The renin-angiotensin-aldosterone system
for normal regulation of blood pressure and sodium and potassium
homeostasis, in Hypertension: Pathophysiology, Diagnosis and Manage-
ment, edited by LARAGH JH, BRENNER B, New York, Raven Press,
1990, pp 1287–1318
2. BAXTER JD, PERLOFF D, HSUEH W, BIGLIERI EG: The endocrinology
of hypertension, in Endocrinology and Metabolism, edited by FELIG P,
BAXTER JD, BROADUS AE, FROHMAN LH, New York, McGraw-Hill
Company, 1995, pp 693–788
3. FERNANDEZ LA, TWICKLER J, MEAD A: Neovascularization produced
by angiotensin II. J Lab Clin Med 105:141–145, 1985
4. PELLICER A, PALUMBO A, DECHERNEY AH, NAFTOLIN F: Blockage of
ovulation by an angiotensin antagonist. Science 240:1660–1661, 1988
5. SAMANI NJ, SWALES JD, BRAMMAR WJ: Expression of the renin gene
in extra-renal tissues of the rat. Biochem J 253:907–910, 1988
6. JONES CA, SIGMUND CD, MCGOWAN RA, KANE-HAAS CM, GROSS
KW: Expression of murine renin genes during fetal development. Mol
Endocrinol 4:375–383, 1990
7. PAUL M, WAGNER J, DZAU VJ: Gene expression of the renin-
angiotensin system in human tissues: Quantitative analysis by the
polymerase chain reaction. J Clin Invest 91:2058–2064, 1993
8. IWAI N, INAGAMI T, OHMICHI N, KINOSHITA M: Renin is expressed in
rat macrophage/monocyte cells. Hypertension 27:399–403, 1996
9. DZAU VJ, INGELFINGER JR, PRATT RE: Regulation of tissue renin and
angiotensin gene expressions. J Cardiovasc Pharm 8(Suppl 10):S11–
S16, 1986
10. INGELFINGER JR, PRATT RE, ELLISON KE, DZAU VJ: Sodium regula-
tion of angiotensinogen mRNA expression in rat kidney cortex and
medulla. J Clin Invest 78:1311–1315, 1986
11. NAKAMURA N, SOUBRIER F, MENARD J, PANTHIER JJ, ROUGEON F,
CORVOL P: Nonproportional changes in plasma renin concentration,
renal renin content, and rat renin messenger RNA. Hypertension
7:855–859, 1985
12. LUDWIG G, GANTEN D, MURAKAMI K, FASCHING U, HACKENTHAL E:
Relationship between renin mRNA and renin secretion in adrenalec-
tomized, salt-depleted, or converting enzyme inhibitor-treated rats.
Mol Cell Endocrinol 50:223–229, 1987
13. MCGOWAN RA, GROSS KW, WILSON CM: Effect of androgen and
thyroid hormones on renin-1 messenger ribonucleic acid levels in
mouse submandibular gland. Mol Cell Endocrinol 56:271–276, 1988
14. TRONIK D, ROUGEON F: Thyroxine and testosterone transcriptionally
regulate renin gene expression in the submaxillary gland of normal
and transgenic mice carrying extra copies of the Ren2 gene. FEBS Lett
234:336–340, 1988
15. FUKAMIZU A, SEO MS, HATAE T, YOKOYAMA M, NOMURA T, KATSUKI
M, MURAKAMI K: Tissue-specific expression of the human renin gene
in transgenic mice. Biochem Biophys Res Commun 165:826–832, 1989
16. SIGMUND CD, JONES CA, KANE CM, WU C, LANG JA, GROSS KW:
Regulated tissue- and cell-specific expression of the human renin gene
in transgenic mice. Circ Res 70:1070–1079, 1992
17. SUN J, ODDOUX C, LAZARUS A, GILBERT MT, CATANZARO DF:
Promoter activity of human renin 59 flanking DNA sequences is
activated by the pituitary-specific transcription factor Pit-1. J Biol
Chem 268:1505–1508, 1993
18. BURT DW, NAKAMURA N, KELLEY P, DZAU VJ: Identification of
negative and positive regulatory elements in the human renin gene.
J Biol Chem 264:7357–7362, 1989
19. GILBERT MT, SUN J, YAN Y, ODDOUX C, LAZARUS A, TANSEY WP,
LAVIN TN, CATANZARO DF: Renin gene promoter activity in GC cells
is regulated by cAMP and thyroid hormone through Pit-1-dependent
mechanisms. J Biol Chem 269:28049–28054, 1994
20. BORENSZTEIN P, GERMAIN S, FUCHS S, PHILIPPE J, CORVOL P, PINET F:
Cis-regulatory elements and trans-acting factors directing basal and
cAMP-stimulated human renin gene expression in chorionic cells. Circ
Res 74:764–773, 1994
21. NARUSE M, SHIZUME K, INAGAMI T: Renin and angiotensins in
cultured mouse adrenocortical tumour cells. Acta Endocrinol 108:545–
549, 1985
22. OKAMURA T, CLEMENS DL, INAGAMI T: Renin, angiotensins, and
angiotensin-converting enzyme in neuroblastoma cells: Evidence for
intracellular formation of angiotensins. Proc Natl Acad Sci USA
78:6940–6943, 1981
23. HOBART PM, FOGLIANO M, O’CONNOR BA, SCHAEFER IM, CHIRGWIN
JM: Human renin gene: Structure and sequence analysis. Proc Natl
Acad Sci USA 81:5026–5030, 1984
24. DE WET JR, WOOD KV, DELUCA M, HELINSKI DR, SUBRAMANI S:
Firefly luciferase gene: Structure and expression in mammalian cells.
Mol Cell Biol 7:725–737, 1987
25. TRONIK D, EKKER M, ROUGEON F: Structural analysis of 59-flanking
regions of rat, mouse and human renin genes reveals the presence of
a transposable-like element in the two mouse genes. Gene 69:71–80,
1988
Chen et al: Down-regulation of hREN promoter by TNFa2054
26. DUNCAN KG, HAIDAR MA, BAXTER JD, REUDELHUBER TL: Regula-
tion of human renin expression in chorionic cell primary cultures. Proc
Natl Acad Sci USA 87:7588–7592, 1990
27. DELLA BRUNA RD, PINET F, CORVOL P, KURTZ A: Opposite regula-
tion of renin gene expression by cyclic AMP and calcium in isolated
mouse juxtaglomerular cells. Kidney Int 47:1266–1273, 1995
28. JOHNS DW, PEACH MJ, GOMEZ RA, INAGAMI T, CAREY RM: Angio-
tensin II regulates renin gene expression. Am J Physiol 259:F882–
F887, 1990
29. TIAN Y, BAUKAL AJ, SANDBERG K, BERNSTEIN KE, BALLA T, CATT KJ:
Properties of AT1a and AT1b angiotensin receptors expressed in
adrenocortical Y-1 cells. Am J Physiol 270(Endocrinol Metab 33):
E831–E839, 1996
30. JIKIHARA H, POISNER AM, HANDWERGER S: Tumor necrosis factor-a
and interleukin-1b inhibit the synthesis and release of renin from
human decidual cells. J Clin Endocrinol Metab 79:195–199, 1995
31. PETROVIC N, KANE CM, SIGMUND CD, GROSS KW: Downregulation
of renin gene expression by interleukin-1. Hypertension 30(part 1):
230–235, 1997
32. SIGMUND CD, OKUYAMA K, INGELFINGER J, JONES CA, MULLINS JJ,
KANE C, KIM U, WU CZ, KENNY L, RUSTUM Y, DZAU VJ, GROSS KW:
Isolation and characterization of renin-expressing cell lines from
transgenic mice containing a renin-promoter viral oncogene fusion
construct. J Biol Chem 265:19916–19922, 1992
33. LANG JA, YANG G, KERN JA, SIGMUND CD: Endogenous human
renin expression and promoter activity in CALU-6, a pulmonary
carcinoma cell line. Hypertension 25:704–710, 1995
34. ROSSIG L, ZOLYOMI A, CATT KJ, BALLA T: Regulation of angiotensin
II-stimulated Ca21 oscillations by Ca21 influx mechanisms in adrenal
glomerulosa cells. J Biol Chem 271:22063–22069, 1996
35. PETERS J, MUNTER K, BADER M, HACKENTHAL E, MULLINS JJ,
GANTEN D: Increased adrenal renin in transgenic hypertensive rats.
TGR(mREN2)27, and its regulation by cAMP, angiotensin II, and
calcium. J Clin Invest 91:742–747, 1993
36. ANTONIPILLAI I, WANG Y, HORTON R: Tumor necrosis factor and
interleukin-1 may regulate renin secretion. Endocrinology 126:273–
278, 1990
37. DAMAS P, CANIVET J-L, DE GROOTE D, VRINDTS Y, ALBERT A,
FRANCHIMONT P, LAMY M: Sepsis, serum cytokine concentrations. Crit
Care Med 25:405–412, 1997
38. WON K-A, BAUMANN H: The cytokine response element of the rat
a1-acid glycoprotein gene is a complex of several interacting regula-
tory sequences. Mol Cell Biol 10:3965–3978, 1990
Chen et al: Down-regulation of hREN promoter by TNFa 2055
